Objective: To analyse positron emission tomography/ computed tomography (PET/CT) imaging and clinical data from patients with non-small cell lung cancer (NSCLC), to identify characteristics of survival beneficiaries of immune checkpoint inhibitors (ICIs) treatment and to establish a survival prediction model. Methods: A retrospective analysis was conducted on PET/CT imaging and clinical parameters of 155 NSCLC patients who underwent baseline PET/CT examination at the Department of Nuclear Medicine, Hebei General Hospital. The Kaplan-Meier curve was employed to compare progression-free survival (PFS) and overall survival (OS) between the ICIs and non-ICIs group and to assess the impact of variables on PFS and OS in the ICIs group. Multivariate Cox proportional hazards regression analysis was conducted with parameters significantly associated with survival in univariate analysis. Results: Significant differences were observed in PFS (chi(2) = 11.910, p = 0.0006) and OS (chi(2) = 8.343, p = 0.0039). Independent predictors of PFS in the ICIs group included smoking history[hazard ratio (HR) = 2.522, 95% confidence interval (CI): 1.044 similar to 6.091, p = 0.0398], SUVmax of the primary lesion(HR = 0.2376, 95%CI: 0.1018 similar to 0.5548, p = 0.0009), MTVp (HR = 0.0755, 95%CI: 0.0284 similar to 0.2003, p < 0.001), and TLGp (HR = 0.1820, 95%CI: 0.0754 similar to 0.4395, p = 0.0002). These were also independent predictors of OS in the ICIs group[HR(95%CI) were 2.729 (1.125 similar to 6.619), 0.2636 (0.1143 similar to 0.6079), 0.0715 (0.0268 similar to 0.1907), 0.2102 (0.0885 similar to 0.4992), both p < 0.05)]. Age was an additional independent predictor of OS (HR = 0.4140, 95%CI: 0.1748 similar to 0.9801, p = 0.0449). Conclusion: Smoking history, primary lesion SUVmax, MTVp, and TLGp were independent predictors of PFS, whilst age, smoking history, SUVmax, MTVp, and TLGp were independent predictors of OS in the ICIs group. Patients without a history of smoking and with SUVmax <= 19.2, MTVp <= 20.745cm(3), TLGp <= 158.62 g, and age <= 60 years benefited more from ICI treatment
基金：
Training project for outstanding talents in clinical medicine in 2021 [2021037]; Key Science and Technology Research Program of the Health Commission of Hebei Province [20241560]
第一作者机构：[1]Hebei Gen Hosp, Dept Nucl Med, Shijiazhuang, Peoples R China[2]Hebei Prov Key Lab Cerebral Networks & Cognit Diso, Shijiazhuang, Peoples R China
通讯作者：
通讯机构：[1]Hebei Gen Hosp, Dept Nucl Med, Shijiazhuang, Peoples R China[2]Hebei Prov Key Lab Cerebral Networks & Cognit Diso, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Zheng Lu,Bian Yanzhu,Hu Yujing,et al.Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer[J].FRONTIERS IN MEDICINE.2025,12:doi:10.3389/fmed.2025.1477275.
APA：
Zheng, Lu,Bian, Yanzhu,Hu, Yujing,Tian, Congna,Zhang, Xinchao...&Qin, Yanan.(2025).Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer.FRONTIERS IN MEDICINE,12,
MLA：
Zheng, Lu,et al."Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer".FRONTIERS IN MEDICINE 12.(2025)
